Harmony Biosciences Holdings, Inc. HRMY · NASDAQ
$37.54 -1.08% (-$0.41)
Summary
89 / 100 · Bulios Score
What speaks for it
- Out of every 100 USD of revenue, 19 USD is left as net profit.
- Revenue grew by 26% a year over the last 3 years.
- It holds more cash than debt: $549.8M against $154.0M.
- The share price is below the Bulios Fair Price.
What to watch
- Earnings per share fell by 3.0% a year over the last 3 years.
- It missed profit estimates 4 times in the last 8 quarters.
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Score in detailPrice
Is it expensive?
Looks cheapBulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Today you pay 12.2 USD for 1 USD of yearly profit. Over the last five years it was 26.8 USD on average.
Valuation in detailIs it growing?
Yes, fastRevenue (USD)
Diluted EPS (USD)
- Analyst estimate
Revenue grew by 40% a year over 5 years. Over the last 3 years it grew by 26% a year. For the next fiscal year analysts expect revenue to grow by 19%. Earnings per share fell by 3.0% a year over the last 3 years.
Growth in detailDoes it make money?
Very wellWhere 100 USD of revenue goes
- Cost of sales 25 USD
- Research and development 23 USD
- Sales and administration 28 USD
- Taxes and other 5.1 USD
- Net profit 19 USD
Net profit, industry median (Biotechnology) -7.1 USD
Out of every 100 USD of revenue, 19 USD is left as net profit.
Profitability in detailIs it financially healthy?
YesIt could repay all its debt from a single year of free cash flow. It holds more cash than debt.
Financial health in detailDoes it pay a dividend?
NoIt pays no dividend.
Dividends in detailWhat do analysts expect?
Mildly positive- Buy 8
- Hold 3
- Sell 2
Today's price within the analysts' price targets
The average target of $49 is 31% above today's price. 62% of the analysts recommend buying.
Analysts in detailWhat does it earn on?
Fiscal year 2023By product
The company reports no revenue by product.
By region
- United States 100%
United States brings in 100% of revenue.
Segments in detail